肥胖是早期类风湿性关节炎治疗反应不佳的危险因素:NORD-STAR研究
Violetta Dubovyk1, Georgios K Vasileiadis1, Tahzeeb Fatima1
1Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden.
RMD open
|April 5, 2024
概括
肥胖与早期类风湿性关节炎 (RA) 治疗反应较差有关. 这一发现不管患者是否接受常规或生物抗风湿药物,都是如此.
科学领域:
- 类风湿病学 类风湿病学
- 临床试验 临床试验
- 肥胖问题研究研究
背景情况:
- 早期类风湿性关节炎 (RA) 管理的目标是缓解.
- 肥胖对早期RA治疗反应的影响尚未完全理解.
- 诺德星试验为研究这种关联提供了一个平台.
研究的目的:
- 评估早期RA中肥胖和治疗反应之间的关联.
- 评估肥胖是否影响对传统和生物抗风湿治疗的反应.
主要方法:
- 从NORD-STAR试验中对793名早期RA患者进行分析.
- 基线体重指数 (BMI) 将参与者分为肥胖 (BMI ≥30 kg/m2) 和非肥胖的组.
- 参与者接受了四种随机治疗之一:常规,克罗尔利祖马布 - 佩戈尔,阿巴塔塞普特或托西祖马布.
- 使用CDAI,SDAI缓解和DAS28-CRP<2.6在48周评估治疗反应.
主要成果:
- 20%的参与者 (161/793) 在基线时患有肥胖.
- 与非肥胖个体相比,肥胖参与者在随访期间表现出更高的疾病活性.
- 肥胖与获得治疗反应 (CDAI,SDAI,DAS28-CRP缓解) 的可能性降低有关.
- 肥胖对治疗反应的影响在所有治疗手臂都是一致的.
结论:
- 肥胖与早期RA中获得良好治疗反应的可能性较低有关.
- 这种关联与接受的特定常规或生物抗风湿治疗是独立的.
- 研究结果强调了在RA治疗策略中考虑肥胖的重要性.
更多相关视频
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
1.1K
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
220
相关概念视频
01:24Obesity
498
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
498
01:21Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Autoimmune Disorders
430
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
430
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162